NASDAQ:ANIK - Anika Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$40.31 -1.10 (-2.66 %)
(As of 05/27/2018 11:36 AM ET)
Previous Close$40.31
Today's Range$40.29 - $41.45
52-Week Range$30.91 - $69.81
Volume127,730 shs
Average Volume239,519 shs
Market Capitalization$594.37 million
P/E Ratio20.57
Dividend YieldN/A
Beta1.77

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Debt-to-Equity RatioN/A
Current Ratio14.74
Quick Ratio13.13

Price-To-Earnings

Trailing P/E Ratio20.57
Forward P/E Ratio37.32
P/E Growth3.73

Sales & Book Value

Annual Sales$113.42 million
Price / Sales5.24
Cash Flow$2.3061 per share
Price / Cash17.48
Book Value$17.89 per share
Price / Book2.25

Profitability

EPS (Most Recent Fiscal Year)$1.96
Net Income$31.81 million
Net Margins17.64%
Return on Equity10.05%
Return on Assets9.32%

Miscellaneous

Employees123
Outstanding Shares14,740,000

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) issued its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.25 by $0.71. The biotechnology company earned $21.30 million during the quarter, compared to analysts' expectations of $24.34 million. Anika Therapeutics had a net margin of 17.64% and a return on equity of 10.05%. The firm's revenue was down 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.37 earnings per share. View Anika Therapeutics' Earnings History.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Anika Therapeutics.

What price target have analysts set for ANIK?

3 brokerages have issued 1 year target prices for Anika Therapeutics' shares. Their predictions range from $39.00 to $68.00. On average, they expect Anika Therapeutics' share price to reach $53.50 in the next year. View Analyst Ratings for Anika Therapeutics.

What are Wall Street analysts saying about Anika Therapeutics stock?

Here are some recent quotes from research analysts about Anika Therapeutics stock:
  • 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (5/7/2018)
  • 2. Barrington Research analysts commented, "We expect gross margin to bounce back by a few hundred basis points as the year progresses." (5/4/2018)

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 60)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 43)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 46)
  • Mr. Richard Hague, Chief Commercial Officer (Age 58)
  • Mr. Thomas M. Finnerty, Chief HR Officer (Age 60)

Has Anika Therapeutics been receiving favorable news coverage?

Media stories about ANIK stock have trended somewhat positive on Sunday, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anika Therapeutics earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.96%), Kayne Anderson Rudnick Investment Management LLC (11.58%), Dimensional Fund Advisors LP (6.31%), SHERWOOD CHARLES H (5.15%), Stifel Financial Corp (1.76%) and Wells Fargo & Company MN (1.48%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Fisher Asset Management LLC, Spark Investment Management LLC, Russell Investments Group Ltd., KBC Group NV, Virginia Retirement Systems ET AL and Barclays PLC. Company insiders that have sold Anika Therapeutics company stock in the last year include Charles H Sherwood and Richard Hague. View Insider Buying and Selling for Anika Therapeutics.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Kayne Anderson Rudnick Investment Management LLC, Millennium Management LLC, BlackRock Inc., Baird Financial Group Inc., Dimensional Fund Advisors LP, 6 Meridian and WINTON GROUP Ltd. View Insider Buying and Selling for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $40.31.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $594.37 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (ANIK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  246
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anika Therapeutics (NASDAQ:ANIK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Anika Therapeutics in the last 12 months. Their average twelve-month price target is $53.50, suggesting that the stock has a possible upside of 32.72%. The high price target for ANIK is $68.00 and the low price target for ANIK is $39.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.672.673.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $53.50$62.50$62.50$57.00
Price Target Upside: 32.72% upside8.30% upside8.30% upside3.92% upside

Anika Therapeutics (NASDAQ:ANIK) Consensus Price Target History

Price Target History for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$39.00HighView Rating Details
1/26/2018SidotiInitiated CoverageBuyLowView Rating Details
1/24/2018First AnalysisUpgradeEqual Weight ➝ Overweight$45.00 ➝ $68.00HighView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Anika Therapeutics (NASDAQ:ANIK) Earnings History and Estimates Chart

Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Earnings Estimates

2018 EPS Consensus Estimate: $1.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.24$0.26$0.25
Q2 20182$0.31$0.41$0.36
Q3 20182$0.37$0.41$0.39
Q4 20182$0.50$0.56$0.53
Q1 20191$0.11$0.11$0.11

Anika Therapeutics (NASDAQ ANIK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2018$0.29N/AView Earnings Details
5/2/2018Q1 2018$0.25($0.46)$24.34 million$21.30 millionViewN/AView Earnings Details
2/21/2018Q4 2017$0.41$0.38$29.85 million$29.39 millionViewListenView Earnings Details
10/25/2017Q3 2017$0.41$0.46$27.44 million$27.18 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.44$0.7560$27.20 million$33.50 millionViewN/AView Earnings Details
5/3/2017Q1 2017$0.3750$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.17$0.21$15.54 million$15.25 millionViewN/AView Earnings Details
2/27/2013Q4 2012$0.23$0.42ViewN/AView Earnings Details
10/30/2012Q3 2012$0.16$0.11ViewN/AView Earnings Details
8/1/2012Q2 2012$0.26ViewN/AView Earnings Details
5/3/2012Q1 2012$0.14ViewN/AView Earnings Details
2/29/2012Q4 2011$0.21ViewN/AView Earnings Details
11/2/2011Q3 2011$0.22ViewN/AView Earnings Details
8/4/2011Q2 2011$0.17ViewN/AView Earnings Details
5/4/2011Q1 2011$0.02ViewN/AView Earnings Details
3/9/2011Q4 2010$0.10ViewN/AView Earnings Details
11/8/2010Q3 2010$0.09ViewN/AView Earnings Details
8/9/2010Q2 2010$0.08ViewN/AView Earnings Details
5/10/2010Q1 2010$0.05ViewN/AView Earnings Details
3/16/2010Q4 2009$0.17ViewN/AView Earnings Details
10/27/2009Q3 2009$0.10$0.13ViewN/AView Earnings Details
7/22/2009Q2 2009$0.08$0.08ViewN/AView Earnings Details
4/28/2009Q1 2009$0.09$0.05ViewN/AView Earnings Details
3/5/2009Q4 2008$0.13$0.10ViewN/AView Earnings Details
11/3/2008Q3 2008$0.12$0.10ViewN/AView Earnings Details
7/22/2008Q2 2008$0.05$0.07ViewN/AView Earnings Details
4/30/2008Q1 2008$0.08$0.05ViewN/AView Earnings Details
3/5/2008Q4 2007$0.13$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Anika Therapeutics (NASDAQ:ANIK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Anika Therapeutics (NASDAQ ANIK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.56%
Insider Trading History for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ ANIK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2017Richard HagueInsiderSell5,250$54.48$286,020.00View SEC Filing  
10/23/2017Charles H SherwoodCEOSell22,228$60.06$1,335,013.68158,297View SEC Filing  
10/20/2017Charles H SherwoodCEOSell5,991$60.04$359,699.64158,297View SEC Filing  
10/16/2017Charles H SherwoodCEOSell3,293$60.04$197,711.72View SEC Filing  
10/13/2017Charles H SherwoodCEOSell7,124$60.08$428,009.92View SEC Filing  
7/27/2017Charles H SherwoodCEOSell63,799$50.79$3,240,351.21174,705View SEC Filing  
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03246,740View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.7515,845View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.6038,513View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.9014,165View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anika Therapeutics (NASDAQ ANIK) News Headlines

Source:
DateHeadline
Anika to buy back $30M in stock via accelerated programAnika to buy back $30M in stock via accelerated program
seekingalpha.com - May 23 at 5:23 PM
Anika Therapeutics Announces $30 Million Accelerated Share RepurchaseAnika Therapeutics Announces $30 Million Accelerated Share Repurchase
finance.yahoo.com - May 23 at 5:23 PM
Weakness Seen in Anika Therapeutics (ANIK) Estimates: Should You Stay Away?Weakness Seen in Anika Therapeutics (ANIK) Estimates: Should You Stay Away?
www.zacks.com - May 18 at 9:02 AM
ANIKA THERAPEUTICS INCANIKA THERAPEUTICS INC
www.finanznachrichten.de - May 8 at 5:23 PM
Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy CongressAnika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress
finance.yahoo.com - May 8 at 5:23 PM
Anika Therapeutics Inc. (ANIK) Given Average Recommendation of "Hold" by BrokeragesAnika Therapeutics Inc. (ANIK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 7 at 7:12 PM
Zacks Investment Research Downgrades Anika Therapeutics (ANIK) to SellZacks Investment Research Downgrades Anika Therapeutics (ANIK) to Sell
www.americanbankingnews.com - May 7 at 5:28 PM
Your Daily Pharma Scoop: Alnylam Update, Malinckrodts Adcom Failure, Anikas Drug RecallYour Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall
seekingalpha.com - May 7 at 8:33 AM
First Analysis Weighs in on Anika Therapeutics Inc.s Q2 2018 Earnings (ANIK)First Analysis Weighs in on Anika Therapeutics Inc.'s Q2 2018 Earnings (ANIK)
www.americanbankingnews.com - May 7 at 2:46 AM
Barrington Research Upgrades Anika Therapeutics (ANIK) to OutperformBarrington Research Upgrades Anika Therapeutics (ANIK) to Outperform
www.streetinsider.com - May 5 at 8:43 AM
Anika Therapeutics (ANIK) Raised to Outperform at Barrington ResearchAnika Therapeutics (ANIK) Raised to Outperform at Barrington Research
www.americanbankingnews.com - May 4 at 10:31 PM
Anika Therapeutics Inc. 2018 Q1 - Results - Earnings Call SlidesAnika Therapeutics Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 4 at 5:15 PM
Anika Therapeutics (ANIK) Cut to C at TheStreetAnika Therapeutics (ANIK) Cut to C at TheStreet
www.americanbankingnews.com - May 4 at 10:28 AM
Edited Transcript of ANIK earnings conference call or presentation 3-May-18 1:00pm GMTEdited Transcript of ANIK earnings conference call or presentation 3-May-18 1:00pm GMT
finance.yahoo.com - May 4 at 8:32 AM
Anika Therapeutics (ANIK) Rating Lowered to Sell at ValuEngineAnika Therapeutics (ANIK) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 11:47 PM
Anika Therapeutics (ANIK) Stock Rating Upgraded by BidaskClubAnika Therapeutics (ANIK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 3 at 11:21 PM
Notable Thursday Option Activity: ANIK, TREE, COUPNotable Thursday Option Activity: ANIK, TREE, COUP
www.nasdaq.com - May 3 at 5:11 PM
Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q1 2018 Results - Earnings Call TranscriptAnika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 5:11 PM
Anika: 1Q Earnings SnapshotAnika: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:30 AM
Anika Therapeutics (ANIK) Posts  Earnings Results, Misses Expectations By $0.71 EPSAnika Therapeutics (ANIK) Posts Earnings Results, Misses Expectations By $0.71 EPS
www.americanbankingnews.com - May 2 at 9:44 PM
Anika Therapeutics EPS of -$0.46Anika Therapeutics EPS of -$0.46
seekingalpha.com - May 2 at 5:23 PM
How Did Anika Therapeutics Inc’s (NASDAQ:ANIK) 12.08% ROE Fare Against The Industry?How Did Anika Therapeutics Inc’s (NASDAQ:ANIK) 12.08% ROE Fare Against The Industry?
finance.yahoo.com - May 2 at 5:23 PM
Anika Reports First Quarter 2018 Financial ResultsAnika Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 5:23 PM
Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest Bancshares, Anika Therapeutics, and Aethlon Medical — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest Bancshares, Anika Therapeutics, and Aethlon Medical — Future Expectations, Projections Moving into 2018
finance.yahoo.com - May 1 at 8:39 AM
Anika Therapeutics (ANIK) Stock Rating Upgraded by Zacks Investment ResearchAnika Therapeutics (ANIK) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 30 at 4:42 PM
Anika Therapeutics (ANIK) Set to Announce Quarterly Earnings on WednesdayAnika Therapeutics (ANIK) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 4:28 AM
Anika to Present at the 2018 Deutsche Bank Health Care Conference on May 8, 2018Anika to Present at the 2018 Deutsche Bank Health Care Conference on May 8, 2018
finance.yahoo.com - April 24 at 5:24 PM
Anika Therapeutics (ANIK) Downgraded to Sell at BidaskClubAnika Therapeutics (ANIK) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - April 20 at 11:54 AM
Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2
finance.yahoo.com - April 18 at 5:32 PM
Anika Therapeutics Inc (ANIK) Given Consensus Rating of "Hold" by AnalystsAnika Therapeutics Inc (ANIK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 12 at 11:20 PM
Anika Therapeutics (ANIK) Downgraded by ValuEngineAnika Therapeutics (ANIK) Downgraded by ValuEngine
www.americanbankingnews.com - April 12 at 10:19 PM
Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair SocietyAnika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society
finance.yahoo.com - April 6 at 8:46 AM
Brokerages Anticipate Anika Therapeutics Inc (ANIK) to Post $0.25 Earnings Per ShareBrokerages Anticipate Anika Therapeutics Inc (ANIK) to Post $0.25 Earnings Per Share
www.americanbankingnews.com - March 30 at 3:24 AM
With A -2.25% Earnings Drop, Is Anika Therapeutics Inc’s (FRA:AKP) A Concern?With A -2.25% Earnings Drop, Is Anika Therapeutics Inc’s (FRA:AKP) A Concern?
finance.yahoo.com - March 29 at 8:44 AM
 Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Buy" from Brokerages Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 26 at 1:32 AM
Edited Transcript of ANIK earnings conference call or presentation 22-Feb-18 2:00pm GMTEdited Transcript of ANIK earnings conference call or presentation 22-Feb-18 2:00pm GMT
finance.yahoo.com - March 22 at 5:24 PM
 Brokerages Set $68.00 Target Price for Anika Therapeutics Inc (ANIK) Brokerages Set $68.00 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 20 at 1:18 AM
Directors Letter Micro Cap Summary - March 2018Director's Letter Micro Cap Summary - March 2018
seekingalpha.com - March 15 at 5:53 PM
Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual MeetingAnika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting
finance.yahoo.com - March 14 at 8:58 AM
Critical Review: Anika Therapeutics (ANIK) and Onconova Therapeutics (ONTX)Critical Review: Anika Therapeutics (ANIK) and Onconova Therapeutics (ONTX)
www.americanbankingnews.com - March 10 at 12:17 PM
Joseph Darling Named CEO and Director of Anika Therapeutics - GlobeNewswire (press release)Joseph Darling Named CEO and Director of Anika Therapeutics - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM
Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting - GlobeNewswire (press release)Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM
 Analysts Set $68.00 Price Target for Anika Therapeutics Inc (ANIK) Analysts Set $68.00 Price Target for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 5 at 5:14 AM
Anika Therapeutics Inc (ANIK) Holdings Lifted by Bbva Compass Bancshares Inc.Anika Therapeutics Inc (ANIK) Holdings Lifted by Bbva Compass Bancshares Inc.
www.americanbankingnews.com - March 1 at 4:56 AM
First Analysis Comments on Anika Therapeutics Incs FY2019 Earnings (ANIK)First Analysis Comments on Anika Therapeutics Inc's FY2019 Earnings (ANIK)
www.americanbankingnews.com - February 28 at 3:18 PM
First Analysis Brokers Decrease Earnings Estimates for Anika Therapeutics Inc (ANIK)First Analysis Brokers Decrease Earnings Estimates for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 27 at 8:38 AM
New Strong Sell Stocks for February 27thNew Strong Sell Stocks for February 27th
finance.yahoo.com - February 27 at 8:37 AM
Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December 31, 2017Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 27 at 8:37 AM
Anika Therapeutics (ANIK) Downgraded by Zacks Investment Research to "Sell"Anika Therapeutics (ANIK) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 26 at 5:24 PM
Equities Analysts Issue Forecasts for Anika Therapeutics Incs Q1 2018 Earnings (ANIK)Equities Analysts Issue Forecasts for Anika Therapeutics Inc's Q1 2018 Earnings (ANIK)
www.americanbankingnews.com - February 26 at 3:18 AM

SEC Filings

Anika Therapeutics (NASDAQ:ANIK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anika Therapeutics (NASDAQ:ANIK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anika Therapeutics (NASDAQ ANIK) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.